Document Detail


Various treatment options for benign prostatic hyperplasia: A current update.
MedLine Citation:
PMID:  22923974     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
In benign prostatic hyperplasia (BPH) there will be a sudden impact on overall quality of life of patient. This disease occurs normally at the age of 40 or above and also is associated with sexual dysfunction. Thus, there is a need of update on current medications of this disease. The presented review provides information on medications available for BPH. Phytotherapies with some improvements in BPH are also included. Relevant articles were identified through a search of the English-language literature indexed on MEDLINE, PUBMED, Sciencedirect and the proceedings of scientific meetings. The search terms were BPH, medications for BPH, drugs for BPH, combination therapies for BPH, Phytotherapies for BPH, Ayurveda and BPH, BPH treatments in Ayurveda. Medications including watchful waitings, Alpha one adrenoreceptor blockers, 5-alpha reductase inhibitors, combination therapies including tamsulosin-dutasteride, doxazosin-finasteride, terazosin-finasteride, tolterodine-tamsulosin and rofecoxib-finasteride were found. Herbal remedies such as Cernilton, Saxifraga stolonifera, Zi-Shen Pill (ZSP), Orbignya speciosa, Phellodendron amurense, Ganoderma lucidum, Serenoa Repens, pumpkin extract and Lepidium meyenii (Red Maca) have some improvements on BPH are included. Other than these discussions on Ayurvedic medications, TURP and minimally invasive therapies (MITs) are also included. Recent advancements in terms of newly synthesized molecules are also discussed. Specific alpha one adrenoreceptor blockers such as tamsulosin and alfuzosin will remain preferred choice of urologists for symptom relief. Medications with combination therapies are still needs more investigation to establish as preference in initial stage for fast symptom relief reduced prostate growth and obviously reduce need for BPH-related surgery. Due to lack of proper evidence Phytotherapies are not gaining much advantage. MITs and TURP are expensive and are rarely supported by healthcare systems.
Authors:
Alankar Shrivastava; Vipin B Gupta
Related Documents :
8824104 - Computerized medication instruction for psychiatric inpatients admitted for acute care.
17270994 - Java-based browsing, visualization and processing of heterogeneous medical data from re...
1807564 - An automatic indexing method for medical documents.
9865034 - Modeling concepts in medicine for medical language understanding.
1047834 - Medical treatment of the adolescent drug abuser. an opportunity for rehabilitative inte...
23687464 - Job security at isfahan university of medical sciences: implications on employees and t...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of mid-life health     Volume:  3     ISSN:  0976-7819     ISO Abbreviation:  J Midlife Health     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-08-27     Completed Date:  2012-10-02     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101552746     Medline TA:  J Midlife Health     Country:  India    
Other Details:
Languages:  eng     Pagination:  10-9     Citation Subset:  -    
Affiliation:
Research Scholar, Jodhpur National University, Jodhpur, Rajasthan, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of menopause on women's periodontium.
Next Document:  Efficacy of levonorgestrel releasing intrauterine system for the treatment of menorrhagia due to ben...